Tilray Brands to Report Q2 2026 Earnings, Expected Loss of $0.20 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Should l Buy TLRY?
Source: Benzinga
- Earnings Forecast: Tilray Brands is expected to report a loss of $0.20 per share for Q2 2026, with projected revenue of $210.95 million, reflecting ongoing challenges in its expansion strategy for the new division, Tilray Medical USA.
- Historical Performance: The company has never reported a profitable quarter since its IPO, indicating persistent pressures in a competitive market that could undermine investor confidence.
- Market Focus: Investors will closely monitor developments in Tilray's new business following the recent federal rescheduling in the U.S., particularly the market strategy for Tilray Medical USA, to assess future growth potential.
- Industry Dynamics: With changing regulations in the U.S. cannabis sector, Tilray's expansion plans may be impacted, necessitating close attention to how the company adapts to market shifts to maintain competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 7.870
Low
8.50
Averages
9.57
High
10.00
Current: 7.870
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Acquires BrewDog Assets, Anticipates Significant Growth Potential
- Acquisition Details: Tilray completed the acquisition of BrewDog's global brand and related intellectual property, UK brewing operations, and eleven strategic brewpubs for £33 million ($44.12 million), despite a 4% drop in stock on Monday.
- Financial Expectations: The company anticipates that the acquired assets will generate approximately $200 million in annual net revenue and adjusted core profit of $6 to $8 million, with cash flow positivity expected to begin in fiscal 2027.
- Market Expansion: This acquisition opens up growth potential for Tilray's U.S. beverage brands in the UK and other international markets, with the total global beverage platform projected to reach $500 million in annual revenue.
- Future Acquisition Plans: Tilray is also negotiating the acquisition of certain BrewDog assets in the U.S. and Australia, with a separate purchase agreement expected to be finalized within 30 days, further strengthening its market position.
See More
Tilray Acquires BrewDog Assets, Stock Under Pressure
- Acquisition Overview: Tilray Brands completed the acquisition of BrewDog's global craft brand assets for £33 million (approximately $44.11 million), which includes U.K. brewing operations and eleven strategic brewpubs, expected to generate around $200 million in annual net revenue despite broader market pressures.
- Revenue Projections: This acquisition is anticipated to boost Tilray's global consolidated net revenue to approximately $1.2 billion, significantly enhancing its beverage portfolio and reflecting the company's growth potential in international markets, particularly in the U.K.
- Market Performance Analysis: Tilray's shares were trading at $7.53, 9.8% below the 20-day simple moving average and 4.1% below the 100-day simple moving average, indicating a bearish trend in the short term, with the stock closer to its 52-week lows.
- Technical Indicator Insights: The relative strength index (RSI) stands at 44.45, considered neutral, suggesting the stock is neither overbought nor oversold; combined with the absence of MACD data, this indicates mixed momentum, prompting caution among traders.
See More
Tilray Acquires BrewDog Assets, Stock Under Pressure
- Acquisition Overview: Tilray Brands completed the acquisition of BrewDog's global craft brand assets for £33 million (approximately $44.11 million), which includes U.K. brewing operations and eleven strategic brewpubs, expected to generate around $200 million in annual net revenue despite broader market pressures.
- Revenue Growth Projection: This acquisition is anticipated to elevate Tilray's global consolidated net revenue to approximately $1.2 billion, significantly enhancing its beverage portfolio and showcasing the company's growth potential in international markets, particularly in the U.K.
- Market Performance Analysis: Tilray's shares are trading at $7.53, which is 9.8% below the 20-day simple moving average and 4.1% below the 100-day simple moving average, indicating a bearish trend in the short term, with the stock closer to its 52-week lows than highs.
- Technical Indicator Insights: The relative strength index (RSI) stands at 44.45, suggesting neutral territory, indicating that the stock is neither overbought nor oversold; combined with the absence of MACD data, this reflects mixed momentum, advising caution for traders.
See More
Tilray Acquires Strategic Assets from BrewDog
- Acquisition Overview: Tilray has acquired BrewDog's global brand, UK brewing operations, and 11 strategic brewpubs for £33 million, expected to generate approximately $200 million in annual net revenue and $6 to $8 million in adjusted EBITDA by fiscal 2027, significantly enhancing Tilray's competitive position in the global beverage market.
- Market Expansion Potential: This acquisition is projected to elevate Tilray's global beverage platform annual revenue to around $500 million, indicating a strategic focus on expanding into untapped international markets, which presents substantial growth opportunities.
- Operational Efficiency Gains: Tilray aims to achieve positive cash flow by early fiscal 2027 through the integration of BrewDog's operations and resources, enhancing overall profitability while providing funding for future brand innovation and market promotion.
- Strategic Investment Intent: Tilray's management emphasizes leveraging their extensive experience in the UK market to revitalize BrewDog's brand and drive profitable growth, ensuring its leadership in the global craft beer movement, reflecting confidence and commitment to future market prospects.
See More
Abbott Laboratories' $23 Billion Acquisition of Exact Sciences Enhances Growth Potential
- Revenue Growth: Abbott Laboratories reported a 5.7% increase in revenue for 2025, reaching $44.3 billion, with adjusted earnings per share (EPS) rising 10% to $5.15, indicating recovery potential in its medical devices and pharmaceuticals sectors, although total revenue has yet to return to pre-pandemic peaks.
- Acquisition Deal: Abbott is finalizing its $23 billion acquisition of Exact Sciences, which saw an 18% revenue increase to $3.2 billion in 2025, expected to enhance Abbott's diagnostics segment and strengthen its foothold in the rapidly growing oncology diagnostics market.
- Market Challenges: Despite strong growth in Abbott's medical devices and pharmaceuticals, sales in its nutrition and diagnostics segments have stagnated due to legal issues and FDA recalls related to FreeStyle Libre 3, leading to diminished investor interest in the stock.
- Future Outlook: Abbott anticipates adjusted EPS for 2026 to be in the range of $5.55 to $5.80, a 10% increase, while the cancer diagnostics market is projected to grow from $109.6 billion in 2024 to $155 billion by 2030, showcasing the company's long-term growth potential in the healthcare sector.
See More
Abbott Labs Increases Dividends for 54 Years, Acquires Exact Sciences
- Dividend Growth Record: Abbott Labs has raised its dividends for 54 consecutive years, with a 6.8% increase in 2023, reflecting its strong cash flow and profitability, which boosts investor confidence and solidifies its status as a 'Dividend King'.
- Acquisition-Driven Growth: Abbott is finalizing a $23 billion acquisition of Exact Sciences, which saw an 18% revenue increase to $3.2 billion in 2025, expected to enhance Abbott's diagnostics segment and strengthen its foothold in the rapidly growing cancer testing market.
- Core Business Recovery: While Abbott's total revenue rose 5.7% to $44.3 billion in 2025 and adjusted EPS increased 10% to $5.15, challenges from lawsuits and recalls related to FreeStyle Libre 3 have impacted some segments, affecting overall market performance.
- Optimistic Market Outlook: Abbott's Volt Pulsed Field Ablation system has received FDA approval, potentially treating 12 million U.S. patients over 65 with atrial fibrillation, with expectations for this number to double in the next two decades, indicating significant growth potential in cardiac care.
See More
Tilray Acquires BrewDog Assets, Anticipates Significant Growth Potential
- Acquisition Details: Tilray completed the acquisition of BrewDog's global brand and related intellectual property, UK brewing operations, and eleven strategic brewpubs for £33 million ($44.12 million), despite a 4% drop in stock on Monday.
- Financial Expectations: The company anticipates that the acquired assets will generate approximately $200 million in annual net revenue and adjusted core profit of $6 to $8 million, with cash flow positivity expected to begin in fiscal 2027.
- Market Expansion: This acquisition opens up growth potential for Tilray's U.S. beverage brands in the UK and other international markets, with the total global beverage platform projected to reach $500 million in annual revenue.
- Future Acquisition Plans: Tilray is also negotiating the acquisition of certain BrewDog assets in the U.S. and Australia, with a separate purchase agreement expected to be finalized within 30 days, further strengthening its market position.
See More
Tilray Acquires BrewDog Assets, Stock Under Pressure
- Acquisition Overview: Tilray Brands completed the acquisition of BrewDog's global craft brand assets for £33 million (approximately $44.11 million), which includes U.K. brewing operations and eleven strategic brewpubs, expected to generate around $200 million in annual net revenue despite broader market pressures.
- Revenue Projections: This acquisition is anticipated to boost Tilray's global consolidated net revenue to approximately $1.2 billion, significantly enhancing its beverage portfolio and reflecting the company's growth potential in international markets, particularly in the U.K.
- Market Performance Analysis: Tilray's shares were trading at $7.53, 9.8% below the 20-day simple moving average and 4.1% below the 100-day simple moving average, indicating a bearish trend in the short term, with the stock closer to its 52-week lows.
- Technical Indicator Insights: The relative strength index (RSI) stands at 44.45, considered neutral, suggesting the stock is neither overbought nor oversold; combined with the absence of MACD data, this indicates mixed momentum, prompting caution among traders.
See More
Tilray Acquires BrewDog Assets, Stock Under Pressure
- Acquisition Overview: Tilray Brands completed the acquisition of BrewDog's global craft brand assets for £33 million (approximately $44.11 million), which includes U.K. brewing operations and eleven strategic brewpubs, expected to generate around $200 million in annual net revenue despite broader market pressures.
- Revenue Growth Projection: This acquisition is anticipated to elevate Tilray's global consolidated net revenue to approximately $1.2 billion, significantly enhancing its beverage portfolio and showcasing the company's growth potential in international markets, particularly in the U.K.
- Market Performance Analysis: Tilray's shares are trading at $7.53, which is 9.8% below the 20-day simple moving average and 4.1% below the 100-day simple moving average, indicating a bearish trend in the short term, with the stock closer to its 52-week lows than highs.
- Technical Indicator Insights: The relative strength index (RSI) stands at 44.45, suggesting neutral territory, indicating that the stock is neither overbought nor oversold; combined with the absence of MACD data, this reflects mixed momentum, advising caution for traders.
See More
Tilray Acquires Strategic Assets from BrewDog
- Acquisition Overview: Tilray has acquired BrewDog's global brand, UK brewing operations, and 11 strategic brewpubs for £33 million, expected to generate approximately $200 million in annual net revenue and $6 to $8 million in adjusted EBITDA by fiscal 2027, significantly enhancing Tilray's competitive position in the global beverage market.
- Market Expansion Potential: This acquisition is projected to elevate Tilray's global beverage platform annual revenue to around $500 million, indicating a strategic focus on expanding into untapped international markets, which presents substantial growth opportunities.
- Operational Efficiency Gains: Tilray aims to achieve positive cash flow by early fiscal 2027 through the integration of BrewDog's operations and resources, enhancing overall profitability while providing funding for future brand innovation and market promotion.
- Strategic Investment Intent: Tilray's management emphasizes leveraging their extensive experience in the UK market to revitalize BrewDog's brand and drive profitable growth, ensuring its leadership in the global craft beer movement, reflecting confidence and commitment to future market prospects.
See More
Abbott Laboratories' $23 Billion Acquisition of Exact Sciences Enhances Growth Potential
- Revenue Growth: Abbott Laboratories reported a 5.7% increase in revenue for 2025, reaching $44.3 billion, with adjusted earnings per share (EPS) rising 10% to $5.15, indicating recovery potential in its medical devices and pharmaceuticals sectors, although total revenue has yet to return to pre-pandemic peaks.
- Acquisition Deal: Abbott is finalizing its $23 billion acquisition of Exact Sciences, which saw an 18% revenue increase to $3.2 billion in 2025, expected to enhance Abbott's diagnostics segment and strengthen its foothold in the rapidly growing oncology diagnostics market.
- Market Challenges: Despite strong growth in Abbott's medical devices and pharmaceuticals, sales in its nutrition and diagnostics segments have stagnated due to legal issues and FDA recalls related to FreeStyle Libre 3, leading to diminished investor interest in the stock.
- Future Outlook: Abbott anticipates adjusted EPS for 2026 to be in the range of $5.55 to $5.80, a 10% increase, while the cancer diagnostics market is projected to grow from $109.6 billion in 2024 to $155 billion by 2030, showcasing the company's long-term growth potential in the healthcare sector.
See More
Abbott Labs Increases Dividends for 54 Years, Acquires Exact Sciences
- Dividend Growth Record: Abbott Labs has raised its dividends for 54 consecutive years, with a 6.8% increase in 2023, reflecting its strong cash flow and profitability, which boosts investor confidence and solidifies its status as a 'Dividend King'.
- Acquisition-Driven Growth: Abbott is finalizing a $23 billion acquisition of Exact Sciences, which saw an 18% revenue increase to $3.2 billion in 2025, expected to enhance Abbott's diagnostics segment and strengthen its foothold in the rapidly growing cancer testing market.
- Core Business Recovery: While Abbott's total revenue rose 5.7% to $44.3 billion in 2025 and adjusted EPS increased 10% to $5.15, challenges from lawsuits and recalls related to FreeStyle Libre 3 have impacted some segments, affecting overall market performance.
- Optimistic Market Outlook: Abbott's Volt Pulsed Field Ablation system has received FDA approval, potentially treating 12 million U.S. patients over 65 with atrial fibrillation, with expectations for this number to double in the next two decades, indicating significant growth potential in cardiac care.
See More
